Breast cancer is the most prevalent cancer worldwide. With advancements in breast cancer diagnosis and treatment, the prognosis of patients with early-stage cancer has significantly improved. Enhancing the long-term quality of life of patients after antineoplastic therapy, including visual quality, has become a crucial research focus. This review aims to comprehensively summarize dry eye disease adverse reaction resulting from pharmacotherapy for early-stage breast cancer. Through a review of the relevant literature, this study explored the etiology, clinical features, and potential therapeutic strategies for drug-induced dry eye disease in breast cancer treatment. A thorough understanding of the medication-induced dry eye disease adverse reaction aid clinicians in monitoring and managing patients' ocular health more effectively, facilitating early diagnosis and intervention, preventing complications, and ensuring optimal visual protection for patients undergoing breast cancer treatment.

中文翻译：

---

早期乳腺癌药物治疗的干眼病不良反应


乳腺癌是全世界最常见的癌症。随着乳腺癌诊断和治疗的进步，早期癌症患者的预后显着改善。提高抗肿瘤治疗后患者的长期生活质量，包括视觉质量，已成为重要的研究热点。本综述旨在全面总结早期乳腺癌药物治疗引起的干眼病不良反应。本研究通过回顾相关文献，探讨了乳腺癌治疗中药物性干眼病的病因、临床特征以及潜在的治疗策略。全面了解药物引起的干眼病不良反应，有助于临床医生更有效地监测和管理患者的眼部健康，促进早期诊断和干预，预防并发症，并确保接受乳腺癌治疗的患者获得最佳的视力保护。